Država: Malta
Jezik: engleski
Izvor: Medicines Authority
CLARITHROMYCIN
PharOS – Pharmaceutical Oriented Services Limited Lesvou str. (end), Thesi Loggos, Industrial Zone, 144 52 Metamorfossi Attikis,, Greece
J01FA09
CLARITHROMYCIN 500 mg
PROLONGED-RELEASE TABLET
CLARITHROMYCIN 500 mg
POM
ANTIBACTERIALS FOR SYSTEMIC USE
Withdrawn
2011-08-05
Page 1 of 9 PACKAGE LEAFLET: INFORMATION FOR THE USER KLORENISS 500MG PROLONGED-RELEASE FILM-COATED TABLETS CLARITHROMYCIN READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What KLORENISS is and what it is used for 2. Before you take KLORENISS 3. How to take KLORENISS 4. Possible side effects 5. How to store KLORENISS 6. Further information 1. WHAT KLORENISS IS AND WHAT IT IS USED FOR KLORENISS is an antibiotic belonging to a group called the macrolides. Antibiotics stop the growth of bacteria (bugs) which cause infections. KLORENISS tablets are prolonged-release tablets, which means that the active ingredient is released slowly from the tablet so that you only have to take it once a day KLORENISS is used to treat infections such as: - Chest infections such as bronchitis and pneumonia - Throat and sinus infections - Mild to moderate skin and tissue inections such as folliculitis, cellulitis and erysipelas. 2. BEFORE YOU TAKE KLORENISS DO NOT TAKE KLORENISS • If you are allergic (hypersensitive) to clarithromycin or to any of the other ingredients of KLORENISS or other macrolide antibiotics such as erythromycin or azithromycin. • If you are taking ergotamin Pročitajte cijeli dokument
Page 1 of 20 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Kloreniss 500mg prolonged-release film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Clarithromycin citrate Each film-coated tablet contains clarithromycin citrate 638.8 mg equivalent to 500mg clarithromycin Each film-coated tablet contains 293.2 mg lactose For full list of excipients, see section 6.1. _ _ 3. PHARMACEUTICAL FORM Prolonged-release film-coated tablet. Yellow coloured, oblong shaped, biconvex prolonged-release film-coated tablet. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Kloreniss is indicated for the treatment of the following infections caused by clarithromycin susceptible organisms (see sections 4.4 and 5.1). - Acute exacerbation of chronic bronchitis - Mild to moderate community-acquired pneumonia. - Acute bacterial sinusitis (adequately diagnosed) - Bacterial pharyngitis - Skin and soft tissue infections of mild to moderate severity Consideration should be given to official guidance on the appropriate use of antibacterial agents 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS: The usual recommended dosage of Kloreniss in adults is one 500 mg prolonged-release tablet daily to be taken with food. In more severe infections, the dosage can be increased to two 500 mg prolonged-release tablets taken as one dose daily. Dose must be taken at the same time every day. Tablets must be swallowed whole. _Adolescents (12 years and older):_ As for adults. Page 2 of 20 _Elderly patients: _ As for adults. (In case of renal impairment, see below and section 4.3). _ _ _Children under the age of 12 years: _ Kloreniss in the tablet form is not recommended for children aged below 12 years or with body weight le Pročitajte cijeli dokument